Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaker A Mousa

Showing results (51-60 of 435) with videos related to

Pageof 44
Sort By:
Personalized Medicine|May 13, 2018
Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspectiveTaylor Sweezy, Shaker A Mousa
Thrombosis and Haemostasis|September 8, 2004
Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitorShaker A Mousa, S Mohamed
American Journal of Hematology|October 14, 2006
Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopeniaShaker A Mousa, Sarfraz Ahmad
Molecular Biotechnology|February 2, 2013
Potential role of naturally derived polyphenols and their nanotechnology delivery in cancerTasnima Khushnud, Shaker A Mousa
Pharmacogenomics and Personalized Medicine|December 11, 2012
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descentHector Clarke, Shaker A Mousa
Molecular Neurobiology|August 14, 2020
Neurodegenerative Diseases and Cell ReprogrammingAbeer Sallam, Shaker A Mousa
Current Pharmaceutical Biotechnology|April 19, 2016
Lipid Nanoparticles and their Application in NanomedicineMehdi Rajabi, Shaker A Mousa
Journal of Cellular Biochemistry|December 21, 2005
Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancerSarah Mousa, Shaker A Mousa
Oncology Reports|September 18, 2004
Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacyShaker A Mousa, Seema Mohamed
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 14, 2014
Oral anticoagulants and status of antidotes for the reversal of bleeding riskJoseph Ebright, Shaker A Mousa
Pageof 44

Showing results (51-60 of 435) with videos related to

Sort By:
Pageof 44
Personalized Medicine|May 13, 2018
Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspectiveTaylor Sweezy, Shaker A Mousa
Thrombosis and Haemostasis|September 8, 2004
Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitorShaker A Mousa, S Mohamed
American Journal of Hematology|October 14, 2006
Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopeniaShaker A Mousa, Sarfraz Ahmad
Molecular Biotechnology|February 2, 2013
Potential role of naturally derived polyphenols and their nanotechnology delivery in cancerTasnima Khushnud, Shaker A Mousa
Pharmacogenomics and Personalized Medicine|December 11, 2012
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descentHector Clarke, Shaker A Mousa
Molecular Neurobiology|August 14, 2020
Neurodegenerative Diseases and Cell ReprogrammingAbeer Sallam, Shaker A Mousa
Current Pharmaceutical Biotechnology|April 19, 2016
Lipid Nanoparticles and their Application in NanomedicineMehdi Rajabi, Shaker A Mousa
Journal of Cellular Biochemistry|December 21, 2005
Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancerSarah Mousa, Shaker A Mousa
Oncology Reports|September 18, 2004
Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacyShaker A Mousa, Seema Mohamed
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 14, 2014
Oral anticoagulants and status of antidotes for the reversal of bleeding riskJoseph Ebright, Shaker A Mousa
Pageof 44